Clinical trials: Prevention of Travelers' Diarrhea
Diarrhea
Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)
This is a Phase II b, double-blind, randomized, placebo-controlled study in healthy adults (age 18-65 years) to evaluate the safety, immunogenicity, different diagnostic tools and efficacy of ETVAX.
- Trial name
- NCT03729219
- Testing
- E. coli ETVAX
- Where
- Finland
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Diarrhea
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E.
- Trial name
- NCT01067781
- Testing
- Heat-Labile Enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Diarrhea
Prevention of Traveler's Diarrhea
The prevention of traveller's diarrhea makes use of the selection of foods and drinks, the purification of water, the use of pharmacological substances such as bismuth salicylate and rifaximin (which can only be taken for short…
- Trial name
- NCT06125626
- Testing
- Probiotical
- Where
- Italy
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Diarrhoea
Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin
The aim of the study is to investigate the efficacy of the prophylactic treatment with rifaximin to prevent travellers diarrhoea.
- Trial name
- NCT00979056
- Testing
- Rifaximin, Lactose
- Where
- Germany
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Dr. Philipp Zanger, MD MSc DTM
Diarrhea
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
- Trial name
- NCT00098384
- Testing
- rifaximin
- Where
- Mexico
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- DuPont, Hurbert L., MD
Diarrhea
ETEC Logistics Trial (TREK)
This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate the epidemiology of natural infection with ETEC occurring after transcutaneous immunization in a field setting.
- Trial name
- Trek (NCT00516659)
- Testing
- Heat-Labile Enterotoxin of Escherichia coli (LT)
- Where
- 19 sites in United States, Guatemala and 1 more
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Travelers' Diarrhea
Probiotics and the Prevention of Traveler's Diarrhea
The present study is designed to evaluate the effect of a mixture of probiotics on the prevention of traveler's diarrhea (TD) in subjects who travel to a country with a high risk for developing TD.
- Trial name
- TD (NCT01005849)
- Testing
- Protecflor
- Where
- Italy
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Lallemand SAS
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Prevention of Travelers' Diarrhea
LT Vaccine Patch Self-Administration Study
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered…
- Trial name
- NCT00565461
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Prevention of Travelers' Diarrhea
Traveler's Diarrhea (TD) Automated Process
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
- Trial name
- NCT00751777
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Traveler's Diarrhea
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea.
- Trial name
- NCT02736539
- Testing
- CBS 2004 (galacto-oligosaccharides)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clasado Biosciences Ltd
Traveler's Diarrhea
Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study
The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses. The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the…
- Trial name
- NCT00672035
- Testing
- Biological: heat-labile enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Diarrhea
Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
The purpose of this study is to determine the efficacy of Bio-K+ CL1285 in reducing traveler's diarrhea.
- Trial name
- NCT00737412
- Testing
- Probiotic: Bio-K+ CL1285
- Where
- 4 sites in Canada
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Diarrhea
Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I
The purpose of this study is to assess anti-CFA/I and anti-CfaE BIgG safety and to determine protective efficacy of anti-CFA/I and anti-CfaE BIgG against diarrhea after challenge with H10407, a CFA/I-expressing ETEC strain.
- Trial name
- BIgGI (NCT00435526)
- Testing
- anti-CFA/I bovine IgG, and anti-CfaE bovine IgG
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhea
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD)…
- Trial name
- NCT00328380
- Testing
- Rifaximin
- Where
- 3 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Diarrhea Travelers, Antibiotic Resistant Infection
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among…
- Trial name
- NCT03535272
- Testing
- Bismuth subsalicylate
- Where
- United States
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Travelers' Diarrhea
Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study
The purpose of this study is to evaluate the efficacy of the Travelers' Diarrhea Vaccine System to actively immunize against Enterotoxigenic Escherichia coli disease in a field setting.
- Trial name
- NCT00993681
- Testing
- TD Vaccine System
- Where
- 20 sites in Germany, Guatemala and 2 more
- Volunteers
- 2,036 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.